Tamtam Try Tamtam free
Tempus AI logo

Tempus AI account plan

AI-powered precision medicine platform

At a glance

Tempus AI is a Chicago-based AI diagnostics and healthcare data company with $1,271.8 million FY2025 revenue and more than 3,800 employees.

Tempus AI is a Chicago-based healthcare technology company that runs molecular diagnostic labs (mostly NGS in oncology, plus hereditary testing) and licenses its de-identified multimodal patient database and AI models to pharma and biotech. Its network covers more than 55% of U.S. oncologists and more than 5,000 institution sites, and it works with 19 of the 20 largest public pharmaceutical companies. FY2025 revenue was $1,271.8 million (2024: $693.4 million), with a net loss of $245.0 million and adjusted EBITDA of $(7.4) million. It had more than 3,800 employees at end-2025. Founded by Eric Lefkofsky in 2015, it listed on Nasdaq (TEM) in June 2024; dual-class stock gives the founder, CEO and chairman voting control.

Business units

Strategic priorities

About 25% long-term growth
Management prefers long-term growth of about 25% a year to a short-term 30% that decelerates; FY2026 revenue guidance is $1.60-$1.605 billion, about 25% growth.
Higher diagnostics reimbursement
FDA approval of the tumor-only xT CDx (May 2026) is expected to give about $80 million of uplift in oncology ASP in 2027, and xF is still in FDA review. The goal is to bring reimbursement per assay more in line with FMI and Guardant.
Multi-year pharma data and model deals
Pharma customers are moving from episodic deals to multi-year collaborations and Lens subscriptions with rented GPU clusters. Data licensing bookings exceeded $550 million year to date in 2026, including BMS (up to $137.5 million over five years).
Expansion beyond oncology
Tempus is extending into neuropsychiatry, cardiology, rare disease and Alzheimer's data; Pathos pays $55 million over five years for an Alzheimer's dataset, and two FDA 510(k) clearances (ECG-PH and ECG-MR) extend its AI cardiology footprint.
AI throughout diagnostics and Algos
The company aims to embed generative and agentic AI in every aspect of diagnostics and to sell clinical-grade Algos through its provider network; Algos are attached to more than 40% of orders.
Profitability and positive free cash flow
Adjusted EBITDA turned positive at $25.6 million in Q3 2026, with about $65 million expected for FY2026; about two-thirds of incremental gross profit is reinvested, and free cash flow should turn positive around the end of 2026.

Latest results

In Q3 2026 (quarter ended September 30, 2026) revenue was $411.5 million, up 23% from $334.2 million in Q3 2025. Diagnostics grew 20% to $303.5 million on 32% oncology volume growth, while hereditary revenue grew only 3%; Data and applications grew 33% to $108.1 million, with Insights up 29%. Net loss narrowed to $14.9 million from $80.0 million, and adjusted EBITDA reached $25.6 million against $1.5 million. Nine-month revenue was $1,142.1 million (2025: $904.6 million). Tempus raised FY2026 revenue guidance to $1.60-$1.605 billion and kept adjusted EBITDA guidance at about $65 million; cash and marketable securities were $854.4 million.

Investments and deals

Personalis acquisition (pending)
Merger agreement announced July 20, 2026 at $16.25 per share, an enterprise value of $1.5 billion, mainly in stock with up to 50% in cash; it has cleared regulatory review and the shareholder vote is planned for November 30, 2026.
Ambry Genetics
Closed February 3, 2025 for $375.0 million cash plus 4,843,136 shares, adding hereditary testing that ran about 460,500 tests and added $362.7 million of revenue in 2025.
Paige, OneOme and Center Health
Paige (digital pathology AI, $101.5 million fair value, August 2025), OneOme (pharmacogenetics and a Minneapolis lab, November 2025) and Center Health (August 7, 2026, $5.4 million cash plus shares).
Foundation model and compute
An oncology foundation model built with AstraZeneca and Pathos runs on about 1,008 H200 GPUs; Pathos pays $200 million of data licence fees over three years.
Convertible financing
$750.0 million of 0.75% convertible notes due 2030 (July 2025) and $460.0 million of 0.00% convertible notes due 2032 (May 2026), of which $317.9 million repaid the remaining Ares term loan and revolver.

Challenges and risks

Payer reimbursement
Payment has been received on about 55% of clinical oncology NGS tests and 50% of hereditary tests performed in 2023-2024; possible FDA changes on LDTs add regulatory risk.
Accumulated losses and debt
The accumulated deficit was $2.5 billion at September 30, 2026, and year-end 2025 indebtedness was $1.3 billion.
MRD economics and Personalis integration
Personalis loses money on the MRD tests it runs; per-test gross profit is expected to turn positive around mid-2027, and new risk factors cover integration and key-employee retention.
Hereditary growth slowdown
Hereditary revenue grew only 3% in Q3 2026 as the business laps last year's share gains.
Competition, data access and litigation
Competitors include Foundation Medicine, Guardant, Natera, Flatiron and IQVIA; continued access to de-identified data, privacy laws and a Guardant patent suit filed in June 2024 are named risks.

What leadership says

“We've always said we're more interested in long-term 25% growth than we are in kind of short-term 30% growth that then decelerates.”

Eric Lefkofsky, Founder and CEO · Tempus AI Q3 2026 earnings call, November 2, 2026

“It's gone from like not sticky to crazy sticky.”

Eric Lefkofsky, Founder and CEO · On pharma data subscriptions, Tempus AI Q3 2026 earnings call, November 2, 2026

“Our data business is big and growing, and we have almost no competition.”

Eric Lefkofsky, Founder and CEO · Tempus AI Investor Day, May 29, 2026

“Our compute capacity is probably equal to all of pharma combined.”

Eric Lefkofsky, Founder and CEO · On the AstraZeneca and Pathos foundation model, Tempus AI Investor Day, May 29, 2026

Where a supplier can help

Cloud, storage and compute cost control
Tied to the foundation model investment and data growth: SG&A growth in Q3 2026 included higher cloud storage and software costs, so suppliers of storage optimisation, GPU capacity or FinOps tooling have a clear entry point.
Revenue cycle and payer collections
Tied to the reimbursement challenge: with payment received on only about half of clinical tests, billing, denial management and payer contracting support maps directly to a stated risk.
Integration of acquired labs and teams
Tied to the Personalis, Ambry, Paige, OneOme and Center Health deals: integration services, lab systems harmonisation and HR or retention tooling support a company absorbing several acquisitions.
Pharma-facing data platform tooling
Tied to the priority on multi-year pharma data and model deals: security, privacy compliance and data governance tools help keep de-identified data licensable under HIPAA and GDPR.
Sales enablement for clinical reps
Tied to the push for oncology volume and MRD: a field sales force of about 205 clinical reps with a land-and-expand model is a fit for CRM, territory and sales enablement offers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Tempus AI?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Tempus AI

What does Tempus AI do?

Tempus AI runs molecular diagnostic labs, mainly oncology NGS and hereditary testing, and connects results to clinical data. It licenses its de-identified multimodal database and AI models to pharma and biotech companies.

What is Tempus AI's revenue?

FY2025 revenue was $1,271.8 million, up from $693.4 million in 2024. For FY2026 the company guides to $1.60-$1.605 billion, about 25% growth.

How many employees does Tempus AI have?

Tempus had more than 3,800 employees at the end of 2025, including about 205 clinical sales representatives.

Who leads Tempus AI?

Eric Lefkofsky is founder, CEO and chairman, and controls the vote through dual-class stock. Jim Rogers is CFO, Tom Schoenherr is CEO of Diagnostics and Ryan Fukushima is CEO of Data and Apps.

What is Tempus AI's strategy?

It aims for about 25% long-term growth by raising diagnostics reimbursement through FDA approvals, signing multi-year pharma data and model deals, and extending its data and AI beyond oncology into areas such as cardiology and Alzheimer's.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)